Developing Health Care Service System

Metabolic Syndrome Clinical Trial

Official title:

Developing Health Care Service System Based on Participatory Big Data

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04378985
• Other study ID #: 3-2019-0226
• Status: Recruiting
• Phase: N/A
• Start date: December 20, 2019
• Est. completion date: December 30, 2021

Study information

• Verified date: May 2020
• Source: Gangnam Severance Hospital
• Contact: Jiwon Lee, Professor
• Phone: 82-2-2019-3480
• Email: INDI5645[@]yuhs.ac
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

"Increased health risks and diseases are believed to be caused by multilevel interactions of genetic and environmental factors (including lifestyle habits). Considering the recent advancements in genetic analysis, wearable devices, and big data analysis techniques, collecting and analyzing personal genetic information, lifelogs, and environmental data and predicting the exact health risks of individuals could be possible.

Description:

These changes enable the development of healthcare solutions that allow users to actively engage in healthcare and provide appropriate care measures to sufficiently delay or prevent chronic diseases, thereby minimizing the financial losses of the individuals and the society. In particular, chronic diseases such as metabolic syndrome can be prevented or delayed through healthy lifestyle habits. Controversy regarding the effectiveness of using wearable devices and mobile health applications for maintaining lifestyle habits and losing weight exists. Additionally, a study assessing the health of the participants and the disease prevention care for the participants using the genetic data and the lifelog data by the wearable device has not been conducted yet. Therefore, the objective is to operate a lifestyle correction program for examinees who visited a family medicine and health checkup center to develop a user-participation health and disease prevention care system using genetic data and lifelog data. From adults who visited a family medicine and health checkup center, the following should be performed: (1) collect a variety of clinical information, including lifestyle data, physical information, metabolic parameters, genetic information, and metagenomes, which can affect chronic diseases; (2) establish a service model that combines lifestyle data, examination data, and genetic data and analyzes and identifies one's health level through a smartphone application; and (3) examine the effects on the metabolic parameters, lifestyle data, and metagenome (gut microbiome) after using the device (smart healthcare).This pilot study aimed to provide personalized "my data" by linking clinical data and personal lifestyle patterns of the participants who visited a family medicine and examination center.

From adults who visited a family medicine and health check-up center, the following should be performed:

1. Collect a variety of clinical information, including lifestyle data, physical information, metabolic parameters, genetic information, and metagenomes, which can affect chronic diseases

2. Establish a service model that combines lifestyle data, examination data, and genetic data and analyzes and identifies one's health level through a smartphone application

3. Examine the effects on the metabolic parameters, lifestyle data, and metagenome (gut microbiome) after using the device (smart healthcare) "

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 384
• Est. completion date: December 30, 2021
• Est. primary completion date: October 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Korean adults aged between 20 and 65 years who visited a family medicine and health checkup center

2. Individuals who understand and are fluent in Korean language

3. Individuals who provided consent for inclusion in the study

4. Individuals who can complete the study without participating in other intervention studies (medicine, diet, exercise) during the whole research duration

5. Individuals who have no restrictions on their participation in physical activities during the whole research duration

Exclusion Criteria:

1. Individuals who did not provide consent for inclusion in the study or individuals who did not provide complete data

2. Individuals with cognitive dysfunction or inability in using wearable devices

3. Individuals with history of infectious brain diseases, head trauma, thyroid diseases, and substance abuse

4. Individuals with vision, hearing, and speech impairments that can affect examinations

5. Individuals considered unfit to participate in this study by researchers

6. Individuals who do not use smartphones

Related Conditions & MeSH terms

• Metabolic Syndrome

Intervention

Device:
• Wearing a Wearable device (Fitbit inspire HR)
'Wearing a wearable device (the smart watch) for 8 weeks The smart watch to be used in this study is Fitbit Inspire HR. This is a device that has a high worldwide use rate and has active research on its accuracy. It is worn like a normal watch, and it can check heart rate, exercise level, energy consumed, and sleep quality. The values can be checked in real-time on a smartphone application.'

Locations

Country	Name	City	State
Korea, Republic of	Gangnam Severance Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Gangnam Severance Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in metabolic parameter (HOMA-IR) at 8 weeks after smart healthcare intervention	Changes in HOMA-IR (calculated using fasting glucose and insulin level) at 8 weeks after smart healthcare intervention.	8 weeks after smart healthcare intervention
Secondary	Changes in other metabolic parameters, inflammatory parameters, metagenome related to the gut microbiome, and sleep quality, diet, and exercise at 8 weeks after smart healthcare intervention	Changes in lipid profile (total cholesterol, TG, LDL-C, HDL-C levels) at 8 weeks after smart healthcare intervention.	8 weeks after smart healthcare intervention